Amyloidosis Light-chain

• CLINICAL_TRIALS research · 2026-04-24
  Clinical Trial Update: Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis [Phase 2]

  Phase 2 dose schedule study of Elranatamab for newly diagnosed AL amyloidosis; trial is not yet Recruiting.

• CLINICAL_TRIALS withdrawal · 2025-03-06
  Clinical Trial Update: Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) [Phase 1, Phase 2]

  The ALTITUDE trial evaluating venetoclax, daratumumab, and dexamethasone for systemic light-chain (AL) amyloidosis with t(11;14) has been wi…